Galicaftor

DB14894InvestigationalSmall molecule

Galicaftor is under investigation in clinical trial NCT03540524 (A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without...

Mechanism: Pharmacologically active on Cystic fibrosis transmembrane conductance regulator
Curator reviewed
Formula / weight: C₂₈H₂₁F₄NO₇ · 559.47 g/mol (avg)
Code names: GLPG2222

Resolves to

Compound

UNIIJ0IIT8QSQSCAS1918143-53-9ChEMBLCHEMBL4101487

Structure

InChIKeyQVDYQHXNAQHIKH-TZIWHRDSSA-NSMILESOC(=O)C1=CC=C(C=C1)[C@H]1C[C@@H](NC(=O)C2(CC2)C2=CC3=C(OC(F)(F)O3)C=C2)C2=C(O1)C=C(OC(F)F)C=C2

Targets

P13569CFTR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Galicaftor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account